OR WAIT 15 SECS
ICYMI, some of the content featured this week includes articles about a new diversity and equity initiative from Skinbetter Science and Allergan Aesthetics, patient sunscreen savviness, skin of color patients lacking in phase 3 psoriasis trials, plus more.
In case you missed it, some of this week’s featured content includes a new episode of our podcast discussing a recent presentation at the 2020 Skin of Color Update on clinical pearls in kids and teens with skin of color. We also highlighted articles on skin of color patients lacking in phase 3 psoriasis trials, patient sunscreen savviness, positive results from a phase 2b study for sonelokinab in adult patients with psoriasis, a new diversity and equity initiative from Skinbetter Science and Allergan Aesthetics, a new drug application (NDA) acceptance from the U.S. Food and Drug Administration (FDA) for Sol-Gel’s Epsolay in papulopustular rosacea, plus more.
A recent survey shows that many consumers are confused about sunscreen labeling claims regarding sun protection factor (SPF), allergenicity and other features.
Cutaneous squamous cell carcinoma (cSCC) patients need close clinical follow-up after being diagnosed with the skin cancer because subsequent cSCC development is likely in the following months and years.
An overwhelming majority of subjects in phase 3 psoriasis clinical trials are Caucasian, leaving unanswered questions about how one’s ethnicity or race might impact the safety and efficacy of today’s psoriasis treatments, according to a research letter published August 7 in the British Journal of Dermatology.
In this episode, Candrice Heath, M.D., sits down to discuss her recent presentation at the 2020 Skin of Color Update about clinical pearls for kids, tweens and teens with skin of color. Dr. Heath also explains the most common skin conditions for this patient group, treatment challenges, and much more.
Merck announces positive results from its phase 2b trial evaluating sonelokinab, an investigational anti-IL-17 A/F nanobody, in adult patients with moderate-to-severe chronic plaque psoriasis.
Color-coded and picture labeling on topical psoriasis medications improved psoriasis patients’ knowledge and understanding of how to correctly use the medications, according to a study published April 10 in the Journal of Pharmacy and BioAllied Sciences.
Across all doses, lebrikizumab showed significant dose-dependent improvement in primary study endpoints for improvements in atopic dermatitis, according to data from phase 2b trials.
Allergan Aesthetics and Skinbetter Science announce the launch of The DREAM Initiative, aimed at improving racial diversity and equity in the aesthetics field.
Vinod E. Nambudiri, M.D., MBA, breaks down tools the specialty can use to expand telehealth services to underserved communities.
The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) filing for Sol-Gel’s Epsolay, a 5% microencapsulated benzoyl peroxide cream for the treatment of inflammatory lesions of rosacea or papulopustular rosacea.
Novartis announces their phase 3 study investigating spartalizumab (PDR001) in combination with dabrafenib (Tafinlar) and trametinib (Mekinist) failed to meet its primary endpoint.
This week’s edition of The Mainstream Patient features stories about the difference between sunblock and sunscreen, lip dryness after getting filler, stress and psoriasis, the issues around skin lightening products, plus more.